Adicet Bio, Inc. Tax Withholding Paid on Stock Awards
Adicet Bio, Inc. (ACET) reported Tax Withholding Paid on Stock Awards of $3.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-05
- Adicet Bio, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $3.00K.
- Adicet Bio, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $65.00K, a 37.50% decline year-over-year.
- Adicet Bio, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-03-31 was $104.00K, a 26.24% decline year-over-year.
- Adicet Bio, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2024-03-31 was $141.00K, a 1310.00% increase year-over-year.
- Adicet Bio, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $104.00K, a 26.24% decline from fiscal 2024.
- Adicet Bio, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $141.00K, a 6.00% decline from fiscal 2023.
- Adicet Bio, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $150.00K, a 95.36% decline from fiscal 2022.
- Adicet Bio, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $3.23M.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00K 10-Q · filed 2026-08-05 | $68.00K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $65.00K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $104.00K 10-K · filed 2026-03-12 | |||
| 2025-03-31 | $104.00K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $141.00K 10-K · filed 2026-03-12 | |||
| 2024-03-31 | $141.00K 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $150.00K 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $59.00K 10-Q · filed 2024-11-06 | |||
| 2023-03-31 | $10.00K 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $3.23M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $1.35M 10-Q · filed 2023-11-08 | $1.56M derived: sum of 2 quarters · filed 2023-11-08 | $2.66M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $203.00K 10-Q · filed 2023-11-08 | $1.31M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $1.11M 10-Q · filed 2023-11-08 | |||
| 2020-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $2.00K 10-Q · filed 2020-07-30 | $2.00K derived: sum of 3 quarters · filed 2020-07-30 | $13.00K derived: sum of 4 quarters · filed 2020-07-30 |
| 2020-03-31 | $1.00K 10-Q · filed 2020-05-07 | $1.00K derived: sum of 2 quarters · filed 2020-05-07 | $12.00K derived: sum of 3 quarters · filed 2020-05-07 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $11.00K derived: sum of 2 quarters · filed 2020-03-12 | $20.00K 10-K · filed 2020-03-12 | |
| 2019-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $20.00K 10-Q · filed 2019-11-05 | ||
| 2019-06-30 | $9.00K 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |